NEW YORK (GenomeWeb News) – Baypoint Biosystems said today it has licensed predictive biomarker intellectual property from the University of Texas MD Anderson Cancer Center in Houston.
The privately held company has obtained exclusive, worldwide rights to commercialize certain proteomics IP and clinical biomarkers for predicting therapeutic responses for certain ovarian and breast cancers.
Baypoint Founder and CEO James Erickson said the proteomics technology will provide “our pharmaceutical partners with new insights into how their drugs are working, in which cancers their drugs are most likely to be effective, and how to rationally combine experimental drugs with approved therapeutics.”
Baypoint, which is also based in Houston, is developing predictive tests for ovarian cancer, hormone-dependent breast cancer, HER2-amplified breast cancer and triple receptor-negative breast cancer.
Financial terms of the agreement were not released.